阿帕替尼联合 CapeOX 方案治疗晚期胃癌的临床探讨

Clinical Effect of Apatinib Combined with CapeOX Regimen Chemotherapy in the Treatment of Advanced Gastric Cancer

摘要:

〔摘 要〕 目的：探讨临床应用阿帕替尼联合 CapeOX 方案治疗晚期胃癌的效果。 方法：选取三门峡市第三人民医 院在 2019 年 1 月至 2021 年 1 月诊治的 70 例晚期胃癌患者，将其进行随机分配为对照组和观察组，各 35 例。其中 对照组患者给予 CapeOX 方案化疗，观察组患者给予阿帕替尼联合 CapeOX 方案治疗，比较两组患者肿瘤缓解效果、 毒副反应，治疗前后血清癌胚抗原（CEA）、糖类抗原 199（CA199）水平、健康调查量表（SF–36）评分。 结果：观察组患者总缓解率为 82.86 %，疾病控制率为 94.29 %，均高于对照组的 54.29 %、77.14 %，差异具有统计学意义 （P ＜ 0.05）；两组患者的毒副反应情况比较，差异无统计学意义（P ＞ 0.05）。观察组患者治疗后血清 CEA、 CA199 水平均低于对照组，差异具有统计学意义（P ＜ 0.05）；观察组患者治疗后生理功能、躯体疼痛、精神健康及 精力表现评分均高于对照组，差异具有统计学意义（P ＜ 0.05）。 结论：采用阿帕替尼联合 CapeOX 方案化疗抗肿瘤 效果明显，可控制晚期胃癌患者的疾病进展，改善生存质量。

Abstract:

〔Abstract〕 Objective To investigate the clinical effect of apatinib combined with CapeOX regimen in the treatment of advanced gastric cancer. Methods A total of 70 patients with advanced gastric cancer diagnosed and treated in Sanmenxia Third People’s Hospital from January 2019 to January 2021 were randomly assigned to a control group and an observation group, with 35 patients in each group. The control group was given CapeOX regimen chemotherapy, and the observation group was given apatinib combined with CapeOX regimen. The tumor remission effect, toxic and side effects, the levels of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) and health survey scale (SF-36) scores before and after treatment were compared between the two groups. Results The total remission rate and disease control rate in the observation group were 82.86 % and 94.29 %, respectively, higher than those 54.29 % and 77.14 % in the control group, with statistical significances (P < 0.05). There was no statistically significant difference in toxicity and side effects between the two groups (P > 0.05). After treatment, the levels of serum CEA and CA199 in the observation group were lower than those in the control group, the differences were statistically significant (P < 0.05). After treatment, the scores of physical function, physical pain, mental health and energy performance in the observation group were higher than those in the control group, and the differences were statistically significant (P < 0.05). Conclusion Apatinib combined with CapeOX Chemotherapy has obvious anti-tumor effect, which can control the disease progression and improve the quality of life of patients with advanced gastric cancer.